Over the past three decades, considerable progress has been made in the development and application of precision medicine, particularly in oncology. Greater understanding of the specific and varying genetic bases for cancers has driven the tailored approach and provided greater opportunities for clinical trials to take advantage of patient genetic variability for recruitment and segmentation purposes. However, this can also introduce challenges in clinical trial planning.
In this report, historic data provide insights into the evolution and future of biomarker use in precision medicine.